Athira Pharma Inc (ATHA NASDAQ) stock market data APIs
$0.307
-0.03(-9.8%)
as of April 24, 2025
Athira Pharma Inc Financial Data Overview
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Prev. Close
0.307
Open
0.2806
High
0.313
Low
0.2674
52 wk Range
0.2195-3.67
Market Cap
11 869 K
Shares Outstanding
39 042 K
EPS
-0.39
Beta
3.056
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Athira Pharma Inc data using free add-ons & libraries
Get Athira Pharma Inc Fundamental Data
Athira Pharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -95 805 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-20
- EPS/Forecast: -0.405
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Athira Pharma Inc News
New
With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors
Key Insights Significantly high institutional ownership implies Athira Pharma's stock price is sensitive to their trading actions The top 12 shareholders own 50% of the company Insiders have sold rec...
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Athira Pharma, Inc. Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second hal...
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma, Inc. Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meanin...
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after lis...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
